<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02278146</url>
  </required_header>
  <id_info>
    <org_study_id>PP-01-2014</org_study_id>
    <nct_id>NCT02278146</nct_id>
  </id_info>
  <brief_title>Feasibility Study Evaluating the ParaPatch System</brief_title>
  <official_title>A Multi-center, Open-label, Prospective, Feasibility Study Evaluating the ParaPatch System for the Treatment of Urinary Incontinence and Overactive Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ParaPatch, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ParaPatch, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, open-label, prospective, feasibility study evaluating the ParaPatch System
      for the treatment of urinary incontinence and overactive bladder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Baseline Period

           o The baseline period will allow for washout of any medication affecting bladder
           function and to allow subject to begin her voiding diary.

        -  Prospective data collection will take place in the form voiding diary. Leak frequency,
           and other relevant parameters will be collected.

        -  Inclusion/exclusion criteria will be rechecked at end of baseline.

        -  Qol questionnaires will be completed in the office at the end of baseline period.

        -  Evaluation Period

           o During the evaluation period, the subjects will use the ParaPatch System.

        -  No medications affecting bladder function will be allowed during the evaluation period.

        -  Subjects will complete voiding diaries, during the evaluation period. Data capture to
           include: adverse events, medication use, leak frequency and other relevant parameters.

        -  Qol questionnaires will be completed in the office at the end of evaluation period.

        -  Follow-up Period

           o Subjects will be followed for after the evaluation period to check for residual
           Adverse Events.

        -  No medications affecting bladder function will be allowed during the follow-up period.

        -  Subjects will be called by the clinical coordinator at the end of the Follow-up period
           and asked about potential Adverse Events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Used the ParaPatch System With Adverse Events Through the Completion of the Study</measure>
    <time_frame>up to 3 weeks</time_frame>
    <description>Documentation, follow-up and characterization of all adverse events in all subjects who use the ParaPatch System, through the completion of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stress Incontinence Arm</measure>
    <time_frame>up to 3 weeks</time_frame>
    <description>Percentage of participants with less daily leaks from baseline to 3 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overactive Bladder Arm</measure>
    <time_frame>up to 3 weeks</time_frame>
    <description>Percentage of participants with less daily voids from baseline to 3 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>1) Stress urinary incontinence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stress urinary incontinence. Diagnosed with urinary stress incontinence and treated with the ParaPatch System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2) Overactive bladder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Overactive bladder. Diagnosed with overactive bladder syndrome and treated with the ParaPatch System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ParaPatch</intervention_name>
    <description>A device for the treatment of urinary incontinence</description>
    <arm_group_label>1) Stress urinary incontinence</arm_group_label>
    <arm_group_label>2) Overactive bladder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged from &gt;18 to &lt; 75 years old.

          -  Subject has the ability to read and comprehend English, and to reliably record
             information as required by the Protocol, including the proper completion of the
             questionnaires.

          -  Subject is able to provide written informed consent prior to participation in the
             study.

          -  Diagnosed with either of the following: a) overactive bladder, or b) urinary stress
             incontinence.

        Exclusion Criteria:

          -  Are currently participating or have participated within the past 30 days in any
             clinical investigation involving or impacting urinary or renal function.

          -  Subject has demonstrated or is believed to be at risk of non-compliance with study
             procedures (e.g., for completing the diary or returning for required follow-up
             visits).

          -  Subject has undergone onabotulinumtoxin-A injections of the bladder in the last twelve
             (12) months.

          -  Subject is not suitable for the study for any reason (including overall health,
             pre-existing conditions or medications) in the judgment of the investigator.

          -  Have an untreated recurrent urinary tract infection (&gt; 2 times within the past 6
             months).

          -  Have neurogenic disorders such as Multiple Sclerosis, ALS, or Parkinson s Disease.

          -  Patients with a diagnosis of painful bladder syndrome, other pelvic pain or
             interstitial cystitis.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cindy Santa Cruz</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skyline Urology</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skyline Urology</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2014</study_first_submitted>
  <study_first_submitted_qc>October 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2014</study_first_posted>
  <results_first_submitted>May 23, 2016</results_first_submitted>
  <results_first_submitted_qc>November 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 24, 2017</results_first_posted>
  <last_update_submitted>November 28, 2016</last_update_submitted>
  <last_update_submitted_qc>November 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1) Stress Urinary Incontinence</title>
          <description>Stress urinary incontinence. Diagnosed with urinary stress incontinence and treated with the ParaPatch System
ParaPatch: A device for the treatment of urinary incontinence</description>
        </group>
        <group group_id="P2">
          <title>2) Overactive Bladder</title>
          <description>Overactive bladder. Diagnosed with overactive bladder syndrome and treated with the ParaPatch System
ParaPatch: A device for the treatment of urinary incontinence</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Females diagnosed with either stress urinary incontinence or overactive bladder that met the inclusion criteria</population>
      <group_list>
        <group group_id="B1">
          <title>1) Stress Urinary Incontinence</title>
          <description>Stress urinary incontinence. Diagnosed with urinary stress incontinence and treated with the ParaPatch System
ParaPatch: A device for the treatment of urinary incontinence</description>
        </group>
        <group group_id="B2">
          <title>2) Overactive Bladder</title>
          <description>Overactive bladder. Diagnosed with overactive bladder syndrome and treated with the ParaPatch System
ParaPatch: A device for the treatment of urinary incontinence</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Used the ParaPatch System With Adverse Events Through the Completion of the Study</title>
        <description>Documentation, follow-up and characterization of all adverse events in all subjects who use the ParaPatch System, through the completion of the study.</description>
        <time_frame>up to 3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1) Stress Urinary Incontinence</title>
            <description>Stress urinary incontinence. Diagnosed with urinary stress incontinence and treated with the ParaPatch System
ParaPatch: A device for the treatment of urinary incontinence</description>
          </group>
          <group group_id="O2">
            <title>2) Overactive Bladder</title>
            <description>Overactive bladder. Diagnosed with overactive bladder syndrome and treated with the ParaPatch System
ParaPatch: A device for the treatment of urinary incontinence</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Used the ParaPatch System With Adverse Events Through the Completion of the Study</title>
          <description>Documentation, follow-up and characterization of all adverse events in all subjects who use the ParaPatch System, through the completion of the study.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stress Incontinence Arm</title>
        <description>Percentage of participants with less daily leaks from baseline to 3 weeks.</description>
        <time_frame>up to 3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1) Stress Urinary Incontinence</title>
            <description>Stress urinary incontinence. Diagnosed with urinary stress incontinence and treated with the ParaPatch System
ParaPatch: A device for the treatment of urinary incontinence</description>
          </group>
          <group group_id="O2">
            <title>2) Overactive Bladder</title>
            <description>Overactive bladder. Diagnosed with overactive bladder syndrome and treated with the ParaPatch System
ParaPatch: A device for the treatment of urinary incontinence</description>
          </group>
        </group_list>
        <measure>
          <title>Stress Incontinence Arm</title>
          <description>Percentage of participants with less daily leaks from baseline to 3 weeks.</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overactive Bladder Arm</title>
        <description>Percentage of participants with less daily voids from baseline to 3 weeks.</description>
        <time_frame>up to 3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1) Stress Urinary Incontinence</title>
            <description>Stress urinary incontinence. Diagnosed with urinary stress incontinence and treated with the ParaPatch System
ParaPatch: A device for the treatment of urinary incontinence</description>
          </group>
          <group group_id="O2">
            <title>2) Overactive Bladder</title>
            <description>Overactive bladder. Diagnosed with overactive bladder syndrome and treated with the ParaPatch System
ParaPatch: A device for the treatment of urinary incontinence</description>
          </group>
        </group_list>
        <measure>
          <title>Overactive Bladder Arm</title>
          <description>Percentage of participants with less daily voids from baseline to 3 weeks.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 weeks during the device usage and for 1 week after completing device usage</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1) Stress Urinary Incontinence</title>
          <description>Stress urinary incontinence. Diagnosed with urinary stress incontinence and treated with the ParaPatch System
ParaPatch: A device for the treatment of urinary incontinence</description>
        </group>
        <group group_id="E2">
          <title>2) Overactive Bladder</title>
          <description>Overactive bladder. Diagnosed with overactive bladder syndrome and treated with the ParaPatch System
ParaPatch: A device for the treatment of urinary incontinence</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Fredrick Wolk, MD</name_or_title>
      <organization>Skyline Urology</organization>
      <phone>+1 310.602.5005</phone>
      <email>fred.wolk@skyuro.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

